Alnylam

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Endpoints
Alnylam
RNAi
Alzheimer's disease
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
Akcea Therapeutics
inotersen
Alnylam
Patisiran
Flag link:
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Alnylam
lumasiran
Primary Hyperoxaluria
Flag link:
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Alnylam
lumasiran
Primary Hyperoxaluria
Flag link:
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
CP Wire
Alnylam
EMA
orphan drugs
ALN-TTRsc02
ATTR amyloidosis
Flag link:
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
Alnylam
amyloidosis
ALN-TTRsc02
Flag link:
Biotech companies Alnylam, Dicerna settle trade secrets case
Biotech companies Alnylam, Dicerna settle trade secrets case
Reuters
Alnylam
Dicerna
trade secrets
gene silencing
Flag link:
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran
Flag link:
Pfizer's rare heart disease drug succeeds in late-stage study
Pfizer's rare heart disease drug succeeds in late-stage study
Yahoo/Reuters
Pfizer
clinical trials
tafamidis
transthyretin cardiomyopathy
rare disease
Alnylam
Ionis Pharmaceuticals
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Biopharma Dive
Regeneron
Alnylam
NASH
R&D
drug discovery
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Flag link:
A biopharma CEO's 5 wishes for Trump’s State of the Union address
A biopharma CEO's 5 wishes for Trump’s State of the Union address
Stat
Donald Trump
John Maraganore
Alnylam
drug pricing
FDA
HHS
healthcare reform
opioid crisis
Flag link:
Three Interviews From the J.P. Morgan Healthcare Conference
Three Interviews From the J.P. Morgan Healthcare Conference
Motley Fool
JPMHC 2018
Alnylam
Arena Pharmaceuticals
Spark Therapeutics
Flag link:
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Yahoo/Motley Fool
Alnylam
givosiran
Patisiran
Flag link:
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Endpoints
Alnylam
Sanofi
JPMHC 2018
Patisiran
Flag link:
Alnylam, Sanofi given the all-clear to resume fitusiran trials
Alnylam, Sanofi given the all-clear to resume fitusiran trials
BioPharma Dive
Alnylam
Sanofi
clinical trials
fitusiran
hemophilia
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:

Pages